Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of HFNC During FOB in Patients With Respiratory Failure
Sponsor: Mansoura University
Summary
This prospective interventional study aims to evaluate the safety and efficacy of high-flow nasal cannula (HFNC) oxygen therapy during fiber-optic bronchoscopy in patients with respiratory failure. The study will assess oxygenation, ventilation, , procedural interruptions, adverse events, patient comfort, and clinical outcomes during and after bronchoscopy.
Official title: Role of High Flow Nasal Cannula During Fiber-optic Bronchoscopy in Patients With Respiratory Failure
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-04-12
Completion Date
2027-11
Last Updated
2026-10-19
Healthy Volunteers
No
Interventions
High flow nasal canula
High-flow nasal cannula (HFNC) oxygen therapy will be administered using the Vapotherm Precision Flow Hi-VNI system. HFNC will be initiated approximately 10 minutes before fiber-optic bronchoscopy, maintained throughout the procedure, and continued for 1-2 hours after the procedure. The initial flow rate will be 40 L/min and may be adjusted between 10 and 40 L/min according to clinical requirements. FiO2 will be titrated to maintain the predefined oxygen saturation target (SpO2 ≥95% in most patients and 88-92% in patients with type 2 respiratory failure). Gas temperature will be set at approximately 34°C with 100% relative humidity. Continuous monitoring of SpO2, heart rate, respiratory rate, and blood pressure will be performed during the procedure, with additional arterial blood gas and end-tidal CO2 assessment according to the study protocol.
Locations (1)
Faculty of Medicine, Mansoura University
Al Mansurah, Dakahlia Governorate, Egypt